Will shareholder pressure derail the STAAR–Alcon merger? Why Yunqi Capital wants the deal scrapped

The ongoing merger between STAAR Surgical Company and Alcon Inc. has taken a dramatic turn as Yunqi Capital Limited, a 5.1% shareholder of the American ophthalmic device manufacturer, publicly opposed the latest delay in the voting process. The Hong Kong–based investment firm issued a scathing letter to the STAAR Surgical Company Board of Directors, criticizing the adjournment of the special meeting of stockholders originally scheduled to vote on the USD 1.5 billion acquisition offer from Alcon.

Yunqi Capital, led by Chief Investment Officer Christopher M. Wang, has urged the board to let shareholders vote without further delay and to abandon what it describes as a weak and conflicted sale process. The firm called on the board to terminate the merger agreement with Alcon and instead launch a structured strategic alternatives review that could unlock greater long-term value for investors.

The original merger agreement, announced on August 5, 2025, would see Alcon acquire all outstanding shares of STAAR Surgical Company for USD 28 per share in cash. The deal represents a 51% premium to STAAR’s share price the day before announcement and a 59% premium to its 90-day volume-weighted average price. However, Yunqi Capital now argues that the deal is misaligned with STAAR’s improving fundamentals in its core China market and should be reconsidered in light of evolving demand dynamics.

What are the core concerns raised by Yunqi Capital about the Alcon transaction?

In its letter dated October 25, 2025, Yunqi Capital expressed frustration over the lack of transparency behind the decision to delay the special shareholder meeting to November 6. The investment firm asserted that the adjournment creates a window for STAAR Surgical Company and Alcon to modify the merger agreement in superficial ways aimed at placating dissenting shareholders without addressing core value concerns.

Yunqi Capital further warned that running a new sales process while the Alcon offer remains outstanding could deter alternative bidders and reduce competitive tension. The firm emphasized that initiating a rushed transaction from what it called “a position of weakness” would be unlikely to secure bids that reflect STAAR Surgical Company’s full strategic potential.

Critically, Yunqi also called attention to potential conflicts of interest within the board and management team that it believes may compromise their ability to act in shareholders’ best interests during a sale process. The firm insisted that any new strategic review should take place after the current merger agreement is terminated, and only once STAAR Surgical Company is in a stronger negotiating position.

How does Yunqi Capital view STAAR’s performance in China, and why is that central to its argument?

The core of Yunqi Capital’s opposition lies in the company’s belief that STAAR Surgical Company is already showing signs of a turnaround in China, its largest geographic market. The firm stated that based on its own on-the-ground analysis, demand for STAAR’s Implantable Collamer Lenses (ICLs) has recently seen double-digit growth rates—suggesting a strong resurgence after a period of volatility.

Yunqi urged STAAR Surgical Company to publish its in-market ICL sales volume data from distributors to surgical providers in China. The firm believes such disclosure would demonstrate that underlying demand is improving and counter management’s previously cautious tone on Chinese market conditions. According to Yunqi Capital, suppressing this data misleads shareholders and underplays the value of STAAR Surgical Company’s China business at a pivotal time.

By pointing to a recovery in China, Yunqi is essentially arguing that the Alcon bid undervalues STAAR Surgical Company by failing to incorporate the upside from resurgent demand in the world’s largest myopia treatment market.

What are the terms of the Alcon–STAAR deal and what strategic rationale was given?

Under the merger terms announced in August 2025, Alcon Inc. agreed to acquire STAAR Surgical Company for USD 28 per share in cash, assigning the transaction an enterprise equity value of approximately USD 1.5 billion. The deal is expected to be accretive to Alcon’s earnings by the second year following close, and complements its existing surgical vision correction business with STAAR’s EVO ICL product family.

Alcon emphasized that the acquisition supports its goal of offering a full suite of solutions across the spectrum of myopia, particularly for patients who are not ideal candidates for LASIK. With nearly half the global population projected to be myopic by 2050—and an estimated 500 million people currently suffering from high myopia—the strategic logic behind integrating STAAR’s implantable lens technology is clear.

STAAR Surgical Company’s EVO ICL lenses are designed for minimally invasive vision correction procedures and have gained traction due to their reversibility and ability to treat both myopia and astigmatism. These lenses are placed between the iris and the eye’s natural lens, avoiding removal of corneal tissue and offering a long-term but non-permanent solution.

Alcon framed the acquisition as a natural expansion of its refractive surgery portfolio, enhancing its capability to deliver innovation in a space undergoing rapid global growth. STAAR Surgical Company leadership, including CEO Stephen Farrell and Board Chair Dr. Elizabeth Yeu, publicly supported the transaction as a value-maximizing move that brings near-term certainty and global distribution advantages.

How is institutional and retail investor sentiment shifting as the STAAR–Alcon vote is delayed and shareholders debate whether the current $28 offer reflects fair long‑term value?

Market sentiment around STAAR Surgical Company’s stock has been mixed in the wake of the proposed acquisition. Shares rose significantly following the August announcement due to the sizable premium offered by Alcon. However, Yunqi Capital is not the only investor voicing reservations. Other stakeholders have raised concerns about process transparency, the adequacy of the offer, and whether the deal undervalues STAAR Surgical Company’s long-term growth trajectory—particularly in Asia.

On October 25, 2025, STAAR Surgical Company shares closed at approximately USD 26.27, suggesting investor confidence remains moderately elevated but below the deal price. This reflects market uncertainty about whether the deal will go through at the current terms or if a competing bid or renegotiation could emerge.

The decision to delay the vote appears to have created further ambiguity. While some investors view the extension as a window to refine the deal or secure more support, others interpret it as a sign that internal resistance or lack of alignment may be growing. Institutional investors are now closely watching how the board manages the next steps—especially if public pressure intensifies.

What could happen next if STAAR shareholders reject the Alcon offer?

If the special meeting results in a vote against the merger, STAAR Surgical Company may be forced to reevaluate its strategic direction. Yunqi Capital has outlined what it believes should happen next: a full, competitive strategic alternatives process conducted without the shadow of Alcon’s existing offer, and timed to STAAR’s own operational recovery rather than counterparty preference.

Such a process, if credibly executed, could attract other buyers—either from strategic players or financial sponsors—interested in leveraging STAAR Surgical Company’s rebound in China and its differentiated technology platform. However, time is a critical variable. Any prolonged uncertainty could weigh on employee morale, partner confidence, and product adoption momentum.

From a valuation perspective, Yunqi’s preferred route would likely require STAAR Surgical Company to present a more comprehensive picture of its global growth metrics, China market rebound, and ICL penetration forecasts. Transparency, particularly around in-market lens sales data, would be essential to convincing potential buyers of STAAR’s intrinsic value.

How does the contested STAAR–Alcon acquisition illustrate shifting power dynamics in medtech M&A and signal a broader rise in shareholder activism within high‑growth ophthalmology markets?

The STAAR–Alcon merger battle underscores growing shareholder activism in specialty healthcare sectors—particularly in situations where regional dynamics like China exposure can drive divergent valuation opinions. With refractive surgery and vision correction technologies expanding rapidly, smaller companies like STAAR Surgical Company often face pressure to scale through partnerships or acquisition. However, as this episode shows, the terms and timing of such deals are increasingly being scrutinized.

This also highlights a larger M&A trend in the medtech space: larger players like Alcon seeking differentiated platforms to maintain market leadership, and investors expecting them to pay full value for high-potential assets. The importance of governance, data disclosure, and process integrity will likely remain front and center in future medical device transactions.

For now, all eyes are on the November 6 vote. Whether STAAR Surgical Company proceeds with the Alcon merger or reopens the strategic playbook, the outcome will shape not just its future, but also investor expectations for other growth-stage players in ophthalmology and beyond.

Where the STAAR–Alcon deal stands now: Key shareholder flashpoints and next steps

• Yunqi Capital Limited, a 5.1% shareholder of STAAR Surgical Company, has publicly opposed the decision to delay the shareholder vote on the proposed USD 1.5 billion acquisition by Alcon Inc.

• The investment firm argues that postponing the special meeting prolongs strategic uncertainty and may open the door to revisions in the merger agreement that fail to address core valuation concerns.

• Yunqi Capital maintains that STAAR Surgical Company is beginning to show renewed demand momentum in China, particularly in Implantable Collamer Lens (ICL) procedures, and believes this recovery is not reflected in the USD 28 per share offer price.

• The firm has called for the Board to terminate the current merger agreement and later conduct a disciplined strategic alternatives review from a stronger negotiating position.

• STAAR Surgical Company’s leadership continues to support the Alcon transaction, emphasizing global scale benefits and more predictable value delivery to shareholders.

• Investor sentiment remains divided, with share prices trading below the offer value, indicating both uncertainty about deal completion and debate over what constitutes fair long‑term valuation.

• The outcome of the shareholder vote scheduled for November 6, 2025, is likely to drive the company’s next strategic chapter—either proceeding with the acquisition or reopening the pathway to competing bidders or independent growth.

• The dispute highlights growing shareholder activism in medical device M&A, particularly where regional market recovery and platform‑level technology assets are central to valuations.